CMV-CMI in csCMVi After HSCT
Key facts
- Where
- Suzhou, ChinaSee the site
Where in China
- The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: The First Affiliated Hospital of Soochow UniversityTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The First Affiliated Hospital of Soochow University
- Trial code
- NCT07688759
- Record updated
- 7 July 2026
- Original description
Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key role in viral control.Read full original descriptionShow less
Study of CMV Specific Immune Reconstitution in Patients With Clinical Significant CMV Infection After Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key role in viral control.
This prospective, exploratory study will enroll 40 adult CMV-seropositive patients who experience their first CMV reactivation after allo-HSCT. CMV-specific T cell levels (IFN-γ-producing T cells stimulated by IE-1 and pp65 antigens) will be measured using ELISPOT at four time points: at diagnosis of CMV viremia, 3 weeks after initiating preemptive therapy, at anti-CMV drug withdrawal, and 4 weeks after treatment discontinuation. Patients will be followed for 12 weeks after stopping treatment.
The primary objective is to describe the changes in CMV-specific T cell levels over the therapy. Secondary objectives are to explore the relationship between these levels and the occurrence of refractory CMV infection, recurrent CMV infection, and CMV disease. Findings may help identify patients at high risk of progressing to severe or persistent CMV infection at an early stage of preemptive therapy, enabling personalized intervention strategies.
Inclusion: ≥18 years old and underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT); First CMV reactivation after transplantation; Life expectancy of ≥8 weeks; The participant (or legally acceptable representative, if applicable) has provided written informed consent for the trial.
Exclusion: Resistance to known anti-CMV drugs (ganciclovir, valganciclovir, foscarnet, maribavir, etc.); Recurrence of CMV infection; primary CMV infection in CMV-seronegative recipients (R-); Currently receiving CMV-CTL treatment or lymphocyte infusion.